Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Part of paid clinical trials in Teaneck, New Jersey.

Sponsor
Leonard Feiner, MD, PhD
Study ID
NCT02302989
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate Ranibizumab as prophylaxis against the conversion to neovascular Age-Related Macular Degeneration

Key Dates

First listed
Nov 27, 2014
Start date
May 31, 2015
Status verified
Aug 2018
Primary completion
Jul 31, 2018
Completion
Jul 31, 2018

Study Design

Enrollment
4 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • No Intervention: Observation
    No treatment. Observation only
  • Active Comparator: Quarterly Ranibizumab 0.5
    Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg

Primary Outcome Measure

Conversion to neovascular AMD. (CNV leakage on FA and evidence of any fluid on SD-OCT) [ Time Frame: 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
NJ Retina (Retina Associates of New Jersey)TeaneckNew Jersey07666-
NJ Retina (Retina Associates of New Jersey)VauxhallNew Jersey07088-

Find similar trials in Teaneck, NJ

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
NJ Retina (Retina Associates of New Jersey)· Teaneck, NJNJ Retina (Retina Associates of New Jersey)· Vauxhall, NJ

Related Studies